Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891704966> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2891704966 abstract "e18268 Background: The current standard for VTE management in patients with active malignancy is low molecular weight heparin (LMWH). Direct oral anticoagulants (DOACs) are convenient options, but comparative data is lacking in cancer patients. Methods: An observational cohort study was conducted to identify patients with cancer treated with either enox or riva (institutional preferences) from December 2012 to April 2015. Patients were excluded if they received prophylactic dosing of enox, prior anticoagulation, transitioned to warfarin, or received anticoagulation for less than 15 days unless they had a bleeding event. Results: A total of 182 patients were included: enox (n = 97) and riva (n = 85). Median age was 65 years at initiation for riva vs 57 years for enox, p = 0.0007. Gender was similar between groups (54% male). Fifty-three percent (n = 97) had metastatic disease and 54% (n = 99) were actively receiving chemotherapy when diagnosed with initial VTE. Sixty-five percent (n = 119) were treated for deep venous thrombosis (DVT), 19 percent (n = 35) had pulmonary embolism (PE), and 11 percent (n = 20) had both DVT and PE. More patients initiated riva for extensive VTE’s 48% vs 29% (p = 0.02). Median duration of anticoagulation was 3.1 months in the enox group and 7.1 months in the riva group (p < 0.0001). Recurrent VTE occurred in 3 patients (one on riva). Ten percent of patients (n = 10) had a bleeding event on enox compared to 15 percent on riva (n = 13, p = 0.3). Major bleeds occurred in seven percent (n = 7) in the enox group and 8 percent (n = 7) in the riva group (p = 0.4). One fatal bleed occurred with each anticoagulant. Pharmacodynamic interactions with antiplatelet agents may have contributed to 3 major bleeds (two with riva). Three percent of patients (n = 3) experienced minor symptomatic bleeds on enox compared to six (7%) on riva. Mean time to bleeding will be presented. Conclusions: Riva is a safe and effective alternative to enox for VTE management in cancer patients. Concomitant medications must be reviewed before initiation and during anticoagulant therapy to minimize drug interactions. Randomized trials are needed to directly compare LMWH to DOACs in this population." @default.
- W2891704966 created "2018-09-27" @default.
- W2891704966 creator A5002698865 @default.
- W2891704966 creator A5019939781 @default.
- W2891704966 creator A5024053204 @default.
- W2891704966 creator A5057070022 @default.
- W2891704966 creator A5082560573 @default.
- W2891704966 date "2017-05-20" @default.
- W2891704966 modified "2023-09-27" @default.
- W2891704966 title "Comparative evaluation of the safety and effectiveness of rivaroxaban (riva) and enoxaparin (enox) for treatment of venous thromboembolism (VTE) in cancer patients." @default.
- W2891704966 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e18268" @default.
- W2891704966 hasPublicationYear "2017" @default.
- W2891704966 type Work @default.
- W2891704966 sameAs 2891704966 @default.
- W2891704966 citedByCount "4" @default.
- W2891704966 countsByYear W28917049662018 @default.
- W2891704966 countsByYear W28917049662019 @default.
- W2891704966 crossrefType "journal-article" @default.
- W2891704966 hasAuthorship W2891704966A5002698865 @default.
- W2891704966 hasAuthorship W2891704966A5019939781 @default.
- W2891704966 hasAuthorship W2891704966A5024053204 @default.
- W2891704966 hasAuthorship W2891704966A5057070022 @default.
- W2891704966 hasAuthorship W2891704966A5082560573 @default.
- W2891704966 hasConcept C121608353 @default.
- W2891704966 hasConcept C126322002 @default.
- W2891704966 hasConcept C141071460 @default.
- W2891704966 hasConcept C2776301958 @default.
- W2891704966 hasConcept C2776694085 @default.
- W2891704966 hasConcept C2776884760 @default.
- W2891704966 hasConcept C2777288759 @default.
- W2891704966 hasConcept C2777557582 @default.
- W2891704966 hasConcept C2778205648 @default.
- W2891704966 hasConcept C2778661090 @default.
- W2891704966 hasConcept C2779161974 @default.
- W2891704966 hasConcept C2779399171 @default.
- W2891704966 hasConcept C2780868729 @default.
- W2891704966 hasConcept C2991741193 @default.
- W2891704966 hasConcept C71924100 @default.
- W2891704966 hasConcept C72563966 @default.
- W2891704966 hasConceptScore W2891704966C121608353 @default.
- W2891704966 hasConceptScore W2891704966C126322002 @default.
- W2891704966 hasConceptScore W2891704966C141071460 @default.
- W2891704966 hasConceptScore W2891704966C2776301958 @default.
- W2891704966 hasConceptScore W2891704966C2776694085 @default.
- W2891704966 hasConceptScore W2891704966C2776884760 @default.
- W2891704966 hasConceptScore W2891704966C2777288759 @default.
- W2891704966 hasConceptScore W2891704966C2777557582 @default.
- W2891704966 hasConceptScore W2891704966C2778205648 @default.
- W2891704966 hasConceptScore W2891704966C2778661090 @default.
- W2891704966 hasConceptScore W2891704966C2779161974 @default.
- W2891704966 hasConceptScore W2891704966C2779399171 @default.
- W2891704966 hasConceptScore W2891704966C2780868729 @default.
- W2891704966 hasConceptScore W2891704966C2991741193 @default.
- W2891704966 hasConceptScore W2891704966C71924100 @default.
- W2891704966 hasConceptScore W2891704966C72563966 @default.
- W2891704966 hasLocation W28917049661 @default.
- W2891704966 hasOpenAccess W2891704966 @default.
- W2891704966 hasPrimaryLocation W28917049661 @default.
- W2891704966 hasRelatedWork W2027694144 @default.
- W2891704966 hasRelatedWork W2124028214 @default.
- W2891704966 hasRelatedWork W2469458532 @default.
- W2891704966 hasRelatedWork W2514337416 @default.
- W2891704966 hasRelatedWork W2548586504 @default.
- W2891704966 hasRelatedWork W2548713733 @default.
- W2891704966 hasRelatedWork W2567520591 @default.
- W2891704966 hasRelatedWork W2588072689 @default.
- W2891704966 hasRelatedWork W2770462796 @default.
- W2891704966 hasRelatedWork W2795588879 @default.
- W2891704966 hasRelatedWork W2796963253 @default.
- W2891704966 hasRelatedWork W2802130786 @default.
- W2891704966 hasRelatedWork W2906962247 @default.
- W2891704966 hasRelatedWork W2918078750 @default.
- W2891704966 hasRelatedWork W3000568411 @default.
- W2891704966 hasRelatedWork W3003178326 @default.
- W2891704966 hasRelatedWork W3010006529 @default.
- W2891704966 hasRelatedWork W3015682247 @default.
- W2891704966 hasRelatedWork W3095402110 @default.
- W2891704966 hasRelatedWork W3194983561 @default.
- W2891704966 isParatext "false" @default.
- W2891704966 isRetracted "false" @default.
- W2891704966 magId "2891704966" @default.
- W2891704966 workType "article" @default.